A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 11 2022
20 11 2022
Historique:
pubmed:
25
8
2022
medline:
19
11
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). We describe the The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.
Identifiants
pubmed: 36001862
doi: 10.1200/JCO.22.00266
pmc: PMC9671754
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3828-3838Subventions
Organisme : Department of Health
ID : IS-BRC-1215-20007
Pays : United Kingdom
Références
Nat Commun. 2022 Feb 1;13(1):449
pubmed: 35105882
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:71-97
pubmed: 28437632
Clin Cancer Res. 2017 Jan 1;23(1):263-272
pubmed: 27507616
Gynecol Oncol. 2015 Apr;137(1):14-22
pubmed: 25677060
Int J Cancer. 2014 Oct 15;135(8):1860-8
pubmed: 24623538
Epigenomics. 2014 Jun;6(3):311-27
pubmed: 25111485
J Gynecol Oncol. 2018 Jan;29(1):e17
pubmed: 29185275
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Cancer Epidemiol. 2019 Aug;61:129-132
pubmed: 31238232
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
Oncotarget. 2015 Sep 22;6(28):24627-35
pubmed: 26384365
Gynecol Oncol. 2020 Jun;157(3):624-633
pubmed: 32008795
Gynecol Oncol. 2016 Jun;141(3):511-515
pubmed: 27103178
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):882-8
pubmed: 15159323
Anal Quant Cytopathol Histpathol. 2012 Aug;34(4):195-203
pubmed: 23016466
Sci Transl Med. 2018 Mar 21;10(433):
pubmed: 29563323
Int J Cancer. 2020 May 1;146(9):2628-2635
pubmed: 31523803
J Clin Pathol. 2014 Dec;67(12):1067-71
pubmed: 25281766
PLoS Med. 2013 Nov;10(11):e1001551
pubmed: 24265601
Sci Transl Med. 2013 Jan 9;5(167):167ra4
pubmed: 23303603
Int J Gynecol Cancer. 2013 Jul;23(6):1050-5
pubmed: 23727823
JAMA Oncol. 2021 Aug 01;7(8):1158-1165
pubmed: 34264304
Int J Cancer. 2019 Dec 15;145(12):3194-3206
pubmed: 31199503